HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen
AG Marcelin, B Jarrousse, A Derache, M Ba, M Dakouo… - Aids, 2007 - journals.lww.com
AG Marcelin, B Jarrousse, A Derache, M Ba, M Dakouo, A Doumbia, I Haidara, A Maïga…
Aids, 2007•journals.lww.comEarly failures to stavudine/lamivudine/nevirapine used as a generic fixed-dose combination
in Mali showed resistance mutations in 50% of cases (mostly M184V and Y181C). No
thymidine analogue mutations were seen, suggesting that most nucleoside reverse
transcriptase inhibitors could be used in a second-line regimen. This highlights the
importance of the accessibility of HIV-RNA assays for monitoring treated patients in resource-
poor countries to detect early virological failure in order to preserve future therapeutic …
in Mali showed resistance mutations in 50% of cases (mostly M184V and Y181C). No
thymidine analogue mutations were seen, suggesting that most nucleoside reverse
transcriptase inhibitors could be used in a second-line regimen. This highlights the
importance of the accessibility of HIV-RNA assays for monitoring treated patients in resource-
poor countries to detect early virological failure in order to preserve future therapeutic …
Abstract
Early failures to stavudine/lamivudine/nevirapine used as a generic fixed-dose combination in Mali showed resistance mutations in 50% of cases (mostly M184V and Y181C). No thymidine analogue mutations were seen, suggesting that most nucleoside reverse transcriptase inhibitors could be used in a second-line regimen. This highlights the importance of the accessibility of HIV-RNA assays for monitoring treated patients in resource-poor countries to detect early virological failure in order to preserve future therapeutic options.
Lippincott Williams & Wilkins